Daewoong Pharmaceutical announced on November 20 that it held "NABOTA SYMPOSIUM" at Lotte Signature Hotel in Seoul on November 17 and 18.
The symposium commemorates the achievements of the NABOTA "DWP-450," which gained Canadian approval for the first time in Korea in August. More than 80 Korean plastic surgeons attended the symposium and shared Navota's clinical results.
"The Canadian sales permit is the first result of the recognition of Navota`s quality, safety and effectiveness by the advanced countries," said Park Sung-soo, head of the Nabota business. "With this symposium, I expect Navota to maintain its position as a premium toxin in both domestic and global markets."
Meanwhile, approval screening procedures of the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for Daewoong Pharmaceutical are proceeding smoothly.
It is predicted that Nabota will be available in major advanced countries such as the U.S. in the first half of next year.